Lu-177-DOTATATE
Phase 2Small molecule
Lu-177-DOTATATE is one of 13 small molecule programs targeting Tumors. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
11 competitors in Tumors
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 2
Opdivo
Bristol-Myers SquibbPhase 2
Yervoy
Bristol-Myers SquibbPhase 2
Fludara
SanofiPhase 2
Proleukin
IIovance Biotherapeutics, Inc.
Phase 2
Tazverik
EEpizyme, Inc.
Phase 2
Cytoxan
BBaxter Healthcare Corporation
Phase 2
Lynparza
AstraZenecaPreclinical
Lu-177-DOTATATE
NNational Cancer Institute (NCI)
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Lu-177-DOTATATE. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- NNational Cancer Institute (NCI)